No. of patients (n = 45) | |||
---|---|---|---|
No. | % | ||
Age at diagnosis, years | |||
Median | 60 (range: 32 to 81) | ||
Sex | |||
Male | 30 | 66.7 | |
Female | 15 | 33.3 | |
Primary tumor location | |||
Gastroesophageal junction/fundus | 4 | 8.9 | |
Body | 8 | 17.8 | |
Antrum | 22 | 48.9 | |
Diffuse | 11 | 24.4 | |
Primary tumor tissue for HER2 assessment | |||
Endoscopic biopsy | 38 | 84.4 | |
Surgical resection | 7 | 15.6 | |
Lauren classification | |||
Intestinal | 21 | 46.7 | |
Diffuse | 23 | 51.1 | |
Mixed | 1 | 2.2 | |
WHO classification | |||
Tubular adenocarcinoma | |||
Well differentiated | 1 | 2.2 | |
Moderately differentiated | 18 | 40.0 | |
Poorly differentiated | 13 | 28.9 | |
Mucinous carcinoma | 1 | 2.2 | |
Poorly cohesive carcinoma | 11 | 24.5 | |
Mixed adenocarcinoma | 1 | 2.2 | |
Cell block of malignant effusion (n = 71) | |||
Sample type | |||
Ascitic fluid | 64 | 90.1 | |
Pleural fluid | 7 | 9.9 | |
Cellularity | |||
High (> 10% tumor cells) | 40 | 56.3 | |
Low (≤10% tumor cells) | 31 | 43.7 | |
Time of effusion sample collection | |||
At the diagnosis of metastatic disease before chemotherapy | 23 | 32.4 | |
During or after palliative chemotherapy | 48 | 67.6 |